JP2008528511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528511A5 JP2008528511A5 JP2007552348A JP2007552348A JP2008528511A5 JP 2008528511 A5 JP2008528511 A5 JP 2008528511A5 JP 2007552348 A JP2007552348 A JP 2007552348A JP 2007552348 A JP2007552348 A JP 2007552348A JP 2008528511 A5 JP2008528511 A5 JP 2008528511A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- therapeutic agent
- family
- heart
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (17)
- 第1の治療薬を単独でか、または第2の治療薬と組み合わせて含む、虚血、虚血性心臓外傷、うっ血性心不全、心筋梗塞、冠状動脈疾患および/または心筋症の処置のための組成物であって、該第1の治療薬は、少なくとも第1の単離されたポリペプチド、またはそのスプライスバリアントもしくは活性なフラグメントを含み、
該組成物は、ヒト被験体の心臓への全身送達または局所送達のためのものであり、該治療薬は、FGFファミリーのメンバーまたはEGFファミリーのメンバーであり、該FGFファミリーのメンバーは、FGF5、FGF9、FGF16、またはFGF17であり、EGFファミリーのメンバーは、アンフィレグリン、Epigen、エピレグリン、HB−EGF、またはベータセルリンである、組成物。 - 前記組成物が、さらに第2の治療薬を含む、請求項1に記載の組成物。
- 前記第2の治療薬が、PDGFファミリーのメンバー、IGFファミリーのメンバーおよびサイモシンβ4のうちの1つ以上を含む、請求項2に記載の組成物。
- 前記第2の治療薬が、VEGFファミリーのメンバー、またはその活性なフラグメントである、請求項2に記載の組成物。
- 前記組成物が、さらに少なくとも第3の治療薬を含む、請求項2に記載の組成物。
- 前記第3の治療薬が、FGFファミリーのメンバーを含み、前記第3の治療薬が、EGFファミリーのメンバーである、請求項5に記載の組成物。
- 前記治療薬の少なくとも1つが、融合分子である、請求項1に記載の組成物。
- 前記融合分子が、融合パートナーを含む、請求項7に記載の組成物。
- 前記融合パートナーが、ポリマー、免疫グロブリン分子、スクシニル基、フェチュインA、フェチュインB、アルブミン、ロイシンジッパードメイン、オリゴマー形成ドメイン、マンノース結合タンパク質、マクロファージスカベンジャータンパク質、Fc領域またはこれらのいずれかの活性なフラグメントを含む、請求項8に記載の組成物。
- 生分解性の担体を含む薬学的に許容可能な担体をさらに含む、請求項1に記載の組成物。
- 前記生分解性の担体が、多糖を含む、請求項10に記載の組成物。
- 前記多糖が、ヒアルロン酸、デキストラン、デキストラン硫酸、コンドロイチン硫酸、デルマタン硫酸、ケラタン硫酸、ヘパリン、ヘパラン硫酸および/またはアルギネートを含む、請求項11に記載の組成物。
- 前記組成物が、生物学的マーカーを含む、請求項1に記載の組成物。
- 前記組成物が、ゲル組成物である、請求項1に記載の組成物。
- 被験体における虚血、虚血性心臓外傷、うっ血性心不全、心筋梗塞、冠状動脈疾患および/または心筋症の処置のためのキットであって、請求項1、2または5のいずれか1項に記載の組成物、該組成物を心臓に送達するためのデバイス、および該組成物を心臓に注入するための指示書を含む、キット。
- 前記第1の治療薬が、約1ng〜約10mgの範囲の用量を含む、請求項1に記載の組成物。
- 前記第1の治療薬が、約1ng〜約50mgの量で前記組成物中に存在する、請求項1に記載の組成物。
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64652005P | 2005-01-25 | 2005-01-25 | |
US60/646,520 | 2005-01-25 | ||
US67508605P | 2005-04-27 | 2005-04-27 | |
US60/675,086 | 2005-04-27 | ||
US67585905P | 2005-04-29 | 2005-04-29 | |
US60/675,859 | 2005-04-29 | ||
US70147405P | 2005-07-22 | 2005-07-22 | |
US60/701,474 | 2005-07-22 | ||
US71649105P | 2005-09-14 | 2005-09-14 | |
US60/716,491 | 2005-09-14 | ||
US73981505P | 2005-11-25 | 2005-11-25 | |
US60/739,815 | 2005-11-25 | ||
PCT/US2006/002313 WO2006081190A2 (en) | 2005-01-25 | 2006-01-25 | Compositions and methods for treating cardiac conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008528511A JP2008528511A (ja) | 2008-07-31 |
JP2008528511A5 true JP2008528511A5 (ja) | 2009-03-05 |
JP5058822B2 JP5058822B2 (ja) | 2012-10-24 |
Family
ID=36740983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007552348A Expired - Fee Related JP5058822B2 (ja) | 2005-01-25 | 2006-01-25 | 心臓の状態を処置するための組成物および方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8168588B2 (ja) |
EP (2) | EP2236153A3 (ja) |
JP (1) | JP5058822B2 (ja) |
AT (1) | ATE481978T1 (ja) |
AU (1) | AU2006208241B2 (ja) |
CA (1) | CA2590338A1 (ja) |
DE (1) | DE602006017071D1 (ja) |
HK (1) | HK1118210A1 (ja) |
WO (1) | WO2006081190A2 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
EP2269461B1 (en) | 2004-07-30 | 2017-03-22 | Mayo Foundation For Medical Education And Research | Treating cardiovascular tissue |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
US20100255518A1 (en) | 2006-04-04 | 2010-10-07 | Goix Philippe J | Highly sensitive system and methods for analysis of troponin |
US9765298B2 (en) | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
EP2098244A1 (en) * | 2008-03-04 | 2009-09-09 | Medizinische Hochschule Hannover | Pharmaceutical composition for the treatment of myocardial infarction |
US8623820B2 (en) | 2008-05-02 | 2014-01-07 | University Of Western Ontario | FGF-9 and its use relating to blood vessels |
WO2009145761A1 (en) | 2008-05-27 | 2009-12-03 | Mayo Foundation For Medical Education And Research | Methods and materials for using cells to treat heart tissue |
CN102231987A (zh) * | 2008-11-28 | 2011-11-02 | 上海泽生科技开发有限公司 | 纽兰格林和心脏干细胞 |
WO2010083466A1 (en) * | 2009-01-16 | 2010-07-22 | Cedars-Sinai Medical Center | Methods and compositions for cardiac tissue regeneration |
WO2010144358A1 (en) | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
EP2498796B1 (en) | 2009-11-09 | 2017-12-27 | AAL Scientifics, Inc. | Treatment of heart disease |
US9051358B2 (en) * | 2009-11-19 | 2015-06-09 | Zhejiang University | Nonnatural collagen-like protein and use thereof |
MX2012005976A (es) * | 2009-12-02 | 2012-06-25 | Cardio3 Biosciences Sa | Composiciones farmaceuticas para la estimulacion de los citoblastos. |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
WO2012045096A2 (en) * | 2010-10-01 | 2012-04-05 | The Trustees Of Columbia University In The City Of New York | Compositions and methods of forming cardiac progenitor cells |
JP2013031151A (ja) * | 2011-06-20 | 2013-02-07 | Renesas Electronics Corp | 暗号通信システムおよび暗号通信方法 |
CA2869163A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Central Florida Research Foundation, Inc. | Methods and compositions using fgf-8 to enhance cardiac regeneration and attenuate adverse cardiac remodeling |
WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
CN110946993A (zh) * | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
EP3200808A4 (en) | 2014-10-03 | 2018-05-16 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
KR101778202B1 (ko) * | 2015-06-04 | 2017-09-13 | (주)피앤피바이오팜 | 안정성이 증가된 인간 섬유아세포 성장인자-2 변이체 및 이의 용도 |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
CA3023530C (en) * | 2016-05-24 | 2021-02-23 | Arris Enterprises Llc | Efficient encrypted software distribution mechanism |
WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
US20200155648A1 (en) * | 2017-06-28 | 2020-05-21 | Children's Medical Center Corporation | Promoting lung growth |
EP3727351A4 (en) | 2017-12-20 | 2021-10-06 | Cedars-Sinai Medical Center | MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY |
US20230398187A1 (en) * | 2019-12-24 | 2023-12-14 | Juvena Therapeutics, Inc. | Regenerative Polypeptides and Uses Thereof |
CH717226B1 (it) * | 2020-07-14 | 2021-09-30 | Contrad Swiss Sa | Idrogel per applicazione topica efficace nel limitare la degenerazione di tendini e muscoli. |
US11524998B2 (en) | 2020-07-16 | 2022-12-13 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155214A (en) | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
US5049132A (en) | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
US5269326A (en) | 1991-10-24 | 1993-12-14 | Georgetown University | Method for transvenously accessing the pericardial space via the right auricle for medical procedures |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US20040132190A1 (en) | 1995-02-28 | 2004-07-08 | The Regents Of The University Of California | Gene therapy for myocardial ischemia |
US20030148968A1 (en) | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
US5797870A (en) | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
DE69735622T2 (de) * | 1996-08-16 | 2007-04-12 | MCW Research Foundation, Inc., Milwaukee | Knochen morphogenetisches protein und fibroblasten wachstumsfaktor enthaltende zusammensetzungen und methoden zur induzierung der kardiogenese |
US6518236B1 (en) * | 1996-10-16 | 2003-02-11 | Zymogenetics, Inc. | FGF homologs |
US6048703A (en) | 1996-11-15 | 2000-04-11 | Cephalon, Inc. | Methods for detecting cell apoptosis |
US20040215168A1 (en) | 1997-04-30 | 2004-10-28 | Beth Israel Deaconess Medical Center | Kit for transvenously accessing the pericardial space via the right atrium |
JP4247846B2 (ja) | 1997-07-03 | 2009-04-02 | デュピュイ・スパイン・インコーポレーテッド | 架橋ポリサッカリド薬物キャリア |
US6304769B1 (en) | 1997-10-16 | 2001-10-16 | The Regents Of The University Of California | Magnetically directable remote guidance systems, and methods of use thereof |
GB2332373A (en) * | 1997-12-19 | 1999-06-23 | Merck & Co Inc | Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter |
US6274712B1 (en) | 1997-12-23 | 2001-08-14 | 3-Dimensional Pharmaceuticals, Inc. | Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137 |
CN100350979C (zh) | 1998-02-11 | 2007-11-28 | 加利福尼亚大学董事会 | 核酸和血管活性剂相组合用于加强的基因投递 |
EP1064356A2 (en) * | 1998-03-23 | 2001-01-03 | ZymoGenetics, Inc. | Cardiac-derived stem cells |
WO2000021548A2 (en) * | 1998-10-13 | 2000-04-20 | Chiron Corporation | Angiogenically effective unit dose of fgf and method of administering |
AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
US6333347B1 (en) | 1999-01-29 | 2001-12-25 | Angiotech Pharmaceuticals & Advanced Research Tech | Intrapericardial delivery of anti-microtubule agents |
JP3106191B1 (ja) * | 1999-03-30 | 2000-11-06 | 工業技術院長 | Fgf−5の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物 |
JP5704780B2 (ja) | 1999-08-13 | 2015-04-22 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 脈管形成因子の用量および心筋血流を改善するための投与方法 |
US20020193301A1 (en) | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
US6815418B2 (en) | 1999-08-19 | 2004-11-09 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
US7214369B2 (en) * | 2003-05-05 | 2007-05-08 | Mirus Bio Corporation | Devices and processes for distribution of genetic material to mammalian limb |
US20040023863A1 (en) | 2000-04-06 | 2004-02-05 | Franco Wayne P. | Methods of use growth factors for treating heart disease |
US7547674B2 (en) * | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
KR101015682B1 (ko) * | 2002-10-08 | 2011-02-22 | 아레스 트레이딩 에스.에이. | Il-18bp에 결합할 수 있고 제 2 사이토킨의 활성을저해할 수 있는 사이토킨의 용도 |
CN100379730C (zh) * | 2002-12-02 | 2008-04-09 | 埃科特莱茵药品有限公司 | 嘧啶-磺酰胺及其作为内皮素受体拮抗剂的应用 |
US9433684B2 (en) | 2008-08-19 | 2016-09-06 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
-
2006
- 2006-01-25 WO PCT/US2006/002313 patent/WO2006081190A2/en active Application Filing
- 2006-01-25 EP EP10075218A patent/EP2236153A3/en not_active Withdrawn
- 2006-01-25 US US11/795,915 patent/US8168588B2/en not_active Expired - Fee Related
- 2006-01-25 AU AU2006208241A patent/AU2006208241B2/en not_active Ceased
- 2006-01-25 EP EP06733813A patent/EP1890721B1/en not_active Not-in-force
- 2006-01-25 AT AT06733813T patent/ATE481978T1/de not_active IP Right Cessation
- 2006-01-25 DE DE602006017071T patent/DE602006017071D1/de active Active
- 2006-01-25 CA CA002590338A patent/CA2590338A1/en not_active Abandoned
- 2006-01-25 JP JP2007552348A patent/JP5058822B2/ja not_active Expired - Fee Related
-
2008
- 2008-08-25 HK HK08109414.1A patent/HK1118210A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008528511A5 (ja) | ||
Subbiah et al. | Materials science and design principles of growth factor delivery systems in tissue engineering and regenerative medicine | |
Song et al. | Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP | |
Whelan et al. | Fibrin as a delivery system in wound healing tissue engineering applications | |
Chu et al. | Therapeutic angiogenesis: controlled delivery of angiogenic factors | |
Hajimiri et al. | Growth factor conjugation: strategies and applications | |
Sakiyama-Elbert | Incorporation of heparin into biomaterials | |
Hunt et al. | Hydrogels for tissue engineering and regenerative medicine | |
Chu et al. | The effect of a heparin-based coacervate of fibroblast growth factor-2 on scarring in the infarcted myocardium | |
US20060025343A1 (en) | Angiogenically effective unit dose fo FGF and method of adminstering | |
Worthington et al. | β-Hairpin peptide hydrogels for package delivery | |
Kang et al. | Poly (ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system | |
Layman et al. | Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model | |
Van Hove et al. | Depot-based delivery systems for pro-angiogenic peptides: a review | |
Schesny et al. | Preserved bioactivity and tunable release of a SDF1-GPVI bi-specific protein using photo-crosslinked PEGda hydrogels | |
RU2011101464A (ru) | Гликозилированный пептид glp-1 | |
JP2007526330A5 (ja) | ||
WO2008047241A3 (en) | Modified corticotropin releasing factor peptides and uses thereof | |
JP2010505444A5 (ja) | ||
JP2014526441A5 (ja) | ||
US20200222548A1 (en) | Synthetic bioconjugates | |
JP2003519097A (ja) | 脈管形成因子の用量および心筋血流を改善するための投与方法 | |
WO2001041812A3 (en) | Amphiphilic polymers and polypeptide conjugates comprising same | |
JP2018523703A5 (ja) | ||
JP2010538020A5 (ja) |